Carnegie Capital Asset Management LLC increased its stake in Crispr Therapeutics AG (NASDAQ:CRSP) by 11.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,170 shares of the company’s stock after buying an additional 2,570 shares during the period. Carnegie Capital Asset Management LLC’s holdings in Crispr Therapeutics were worth $1,032,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC grew its holdings in shares of Crispr Therapeutics by 5.9% during the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock valued at $839,000 after buying an additional 986 shares during the last quarter. Moody Aldrich Partners LLC purchased a new stake in Crispr Therapeutics in the second quarter worth approximately $1,838,000. Traynor Capital Management Inc. purchased a new position in shares of Crispr Therapeutics during the 2nd quarter worth $308,000. Nikko Asset Management Americas Inc. boosted its stake in shares of Crispr Therapeutics by 324.3% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after acquiring an additional 1,430,364 shares during the last quarter. Finally, BNP Paribas Arbitrage SA purchased a new position in shares of Crispr Therapeutics during the 2nd quarter worth $41,000. 49.82% of the stock is owned by institutional investors.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at $390,000. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. Insiders own 21.40% of the company’s stock.
CRSP opened at $65.36 on Friday. The firm’s fifty day simple moving average is $58.93 and its two-hundred day simple moving average is $48.44. The company has a market cap of $3.62 billion, a price-to-earnings ratio of -19.00 and a beta of 3.31. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics AG has a 52-week low of $22.22 and a 52-week high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, research analysts forecast that Crispr Therapeutics AG will post 0.65 EPS for the current year.
Several research analysts have recently weighed in on CRSP shares. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Goldman Sachs Group lifted their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. BidaskClub downgraded shares of Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday. Roth Capital lifted their price target on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Finally, TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the stock. Crispr Therapeutics presently has an average rating of “Buy” and a consensus target price of $69.54.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Net Margin
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.